Related Experiment Video
Updated: Jan 30, 2026

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
Pulmonary embolism with migrating thrombus through patent foramen ovale: A case for a mixed pharmacological and
Gloria Santangelo1, Alfonso Ielasi2, Francesco Pattarino1
1Cardiology Division, Azienda Socio Sanitaria Territoriale Bergamo Est, Bolognini Hospital, Seriate (BG), Italy.
Abstract:
A 61-year-old man, admitted to our hospital for bilateral pulmonary embolism, complicated by right renal ischemia and multiple splenic infarcts due to a mobile thrombus entrapped in a patent foramen ovale, has been successfully treated with apixaban 5 mg twice daily followed by transcatheter patent foramen ovale closure. <Learning objective: Apixaban could be a therapeutic alternative to thrombolysis and surgery in patients with warfarin-resistant thrombus straddling in the patent foramen ovale (PFO). Furthermore, apixaban could be a simple and useful option to manage patients undergoing transcatheter PFO closure. Finally, in the evaluation and treatment of PFO, it is necessary to remember that it is associated not only with cryptogenic stroke but also with non-cerebral, paradoxical systemic embolic events such as myocardial infarction renal, infarct, and limb ischemia.>.
Related Concept Videos
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Cardiopulmonary Resuscitation IV: Pharmacological Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation

